Acurx's Novel Lead Antibiotic Candidate Presented at Two Prominent International Scientific Conferences

Oct 3, 2019

Acurx Successfully Completes Ph1 Clinical Trial for ACX-362E in CDI

Aug 28, 2019

Acurx Announces First-In-Man Clinical Trial Data of ACX-362E for CDI

Feb 27, 2019

Acurx Receives FDA Fast Track Designation for ACX-362E for the Treatment of C. difficile infection

Jan 16, 2019

Acurx Pharmaceuticals to Enter Clinical Trials with First-In-Class Antibiotics to Treat Selected Gram-Positive Bacterial Infections

Oct 4, 2018

FDA Grants QIDP Designation to Acurx’s Lead Antibiotic Product Candidate, ACX-362E for Clostridium Difficile Infection

Jun 20, 2018